Influence of hereditary and environmental factors on cytochrome P450 metabolic activity and drug effects
T. G. Khlopushina · 1996 · Doctoral dissertation author’s abstract. Moscow, 1996
What does this source report?
ADK-559/591/676/677 weakly inhibited hepatic monooxygenase activity. ADK-709/790/828/829/910/918 were identified as P450 inducers. This is an enzyme-screening result, not an endurance or clinical-benefit comparison.
- Population and setting
- Mouse hepatic-enzyme screening; 18 adamantane compounds
- Evidence type
- Animal / experimental
- Preparation
- See the original report; formulation details require verification.
- Source language
- Russian
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Original structures and tables require checking against the scan; transcription errors are possible.
- Enzyme induction does not establish detoxification benefits or predict safe human drug combinations.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Dissertation abstract transcription
Source access and review scope
Selected source passages checked; complete methods and risk of bias not appraised.
Recorded source-check date: 2026-10-03. This date does not imply a completed systematic review.
Source provenance: Dissertation; OCR reproduction
Cite and trace this record
Original source: T. G. Khlopushina. Influence of hereditary and environmental factors on cytochrome P450 metabolic activity and drug effects Doctoral dissertation author’s abstract. Moscow, 1996 1996.
Molekul research summary: https://molekul.io/research/adk-cyp-1996. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Bromantane
An adamantane-derived small molecule, also known as Ladasten. The expanded archive connects clinical asthenia studies, operator experiments and preclinical mechanisms, with model-specific limitations and safety findings.
Chlodantane
N-(adamantan-2-yl)-4-chlorobenzamide, an experimental benzamide from the Russian adamantane programme. Its amide linkage distinguishes it from Bromantane’s arylamine.
ADK-918
The para-bromobenzamide counterpart of Chlodantane, N-(adamantan-2-yl)-4-bromobenzamide. It is chemically distinct from Bromantane.
ADK-559
An experimental adamantane code in the 1996 hepatic-enzyme screen. Original structural records and compound-specific pharmacology require further recovery.
ADK-591
An experimental adamantane code in the 1996 hepatic-enzyme screen. Original structural records and compound-specific pharmacology require further recovery.
ADK-676
An experimental adamantane code in the 1996 hepatic-enzyme screen. Original structural records and compound-specific pharmacology require further recovery.
ADK-677
An experimental adamantane code in the 1996 hepatic-enzyme screen. Original structural records and compound-specific pharmacology require further recovery.
ADK-790
An experimental adamantane code in the 1996 hepatic-enzyme screen. Original structural records and compound-specific pharmacology require further recovery.
ADK-828
An experimental adamantane code in the 1996 hepatic-enzyme screen. Original structural records and compound-specific pharmacology require further recovery.
ADK-829
An experimental adamantane code in the 1996 hepatic-enzyme screen. Original structural records and compound-specific pharmacology require further recovery.